efgartigimod alfa-fcab news

All news on efgartigimod alfa-fcab (also known as VYVGART): plants, production capacities, investments and involved companies.

27 August 2026

argenx acquires Forte Biosciences, adds anti‑CD122 antibody FB102

Adds FB102, a first‑in‑class anti‑CD122 with clinical proof‑of‑concept in vitiligo and celiac disease; $77 per‑share tender offer completed and merger closed.
17 August 2026

argenx: Positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis

Primary endpoint met in Phase 3 ALKIVIA: efgartigimod improved mean Total Improvement Score at Week 52 versus placebo; benefit emerged by Week 4 and was sustained across IMNM and DM.
27 July 2026

argenx to acquire Forte Biosciences, adding anti‑CD122 candidate FB102

FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.

Who will be producing efgartigimod alfa-fcab in the future?

Find out with chemXplore Alpha

Learn more